Amendments to the Claims

Listing of Claims

The following Listing of Claims replaces all prior versions and listings of claims in the application.

1. (currently amended) A composition of matter comprising a spray dried solid dispersion, which dispersion

consists ~~essentially~~ of a sparingly water-soluble drug and hydroxypropyl methylcellulose acetate succinate (HPMCAS), said drug being molecularly dispersed and amorphous in said dispersion;

has a drug:polymer weight ratio between 1:0.4 and 1:20; and a test composition of said dispersion satisfies either of the following tests:

(a) ~~providing~~ provides a maximum concentration of said drug in MFD (model fasted duodenal fluid) that is higher by a factor of at least 1.5 relative to a control composition [;] wherein MFD is water which is 82 mM in NaCl, 20 mM in Na_2HPO_4, 47 mM in KH_2PO_4, 14.7 mM in sodium taurocholate and 2.8 mM in 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine to yield a solution pH of about 6.5 and osmotic pressure of about 290 mOsm/kg, or

(b) ~~effecting~~ effects, *in vivo*, a maximal observed blood drug concentration (C_{max}), that is higher by a factor of at least 1.25 relative to a control composition;

wherein ~~the~~ said control composition is identical to ~~the~~ said test composition except that it comprises pure drug in its equilibrium form and does not comprise HPMCAS, or the HPMCAS is replaced by an equal amount of inert, non-adsorbing solid diluent and the test composition and control composition are tested under like ~~or standardized~~ conditions.

2. (canceled)

3. (canceled)

4. (original) A composition as defined in claim 1, wherein said drug is amorphous when undispersed.

5-14. (canceled)

15. (currently amended) A composition of matter comprising a spray dried solid dispersion, which dispersion

consists ~~essentially~~ of a sparingly water-soluble drug and HPMCAS, said drug being molecularly dispersed and amorphous in said dispersion;

effects, *in vivo*, an area under a curve (AUC) plotting the serum or plasma concentration of drug ~~along~~ on the ordinate against time on the abscissa that is higher by a factor of at least 1.25 relative to a control composition comprising an equivalent quantity of undispersed drug; and

has a drug:polymer weight ratio between 1:0.4 and 1:20.

16. (canceled)

17. (original) A composition as defined in claim 15, wherein said drug is amorphous when undispersed.

18-21. (canceled)

22. (original) A composition as defined in claim 1, wherein the concentration of drug in MFD falls to no less than 25% of the maximum supersaturated concentration during the 15 minutes following the time at which the maximum supersaturated concentration is reached.

23. (original) A composition as defined in claim 1, wherein said dispersion is in the form of particles less than 100 μm in diameter.

24-25. (canceled)

26. (original) A composition as defined in claim 15, wherein said dispersion is in the form of particles less than 100 μm in diameter.

27. (canceled)

28. (withdrawn) A composition as defined in claims 1 and 15 wherein said drug is a glycogen phosphorylase inhibitor.

29. (withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

30. (withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

31. (withdrawn) A composition as defined in claims 1 and 15 wherein said drug is a 5-lipoxygenase inhibitor.

32. (withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

33. (withdrawn) A composition as defined in claims 1 and 15 wherein said drug is a corticotropic releasing hormone (CRH) inhibitor.

34. (withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

35. (withdrawn) A composition as defined in claims 1 and 15 wherein said drug is



or a pharmaceutically acceptable salt thereof.

36. (currently amended) A composition as defined in ~~claims~~ claim 1 ~~and~~ or 15 wherein said drug is an antipsychotic.

37. (currently amended) A composition as defined in ~~claims~~ claim 1 ~~and~~ or 15 wherein said drug is ziprasidone.

38. (withdrawn) A composition as defined in claims 1 and 15 wherein said drug is selected from griseofulvin, nifedipine, and phenytoin.

39-48. (canceled)

49. (currently amended) A composition as defined in ~~claims~~ claim 1 ~~and~~ or 15 wherein said dispersion comprises spray dried particles that are solidified in less than 2 seconds.

50. (currently amended) A composition as defined in ~~claims~~ claim 1 ~~and~~ or 15 wherein said particles have a residual solvent content less than 2 wt%.

51. (currently amended) A composition as defined in ~~claims~~ claim 1 ~~and~~ or 15 wherein said particles are spray-dried from a solution in which the concentration of drug in the solvent is less than 20 g/100 g and in which the total solids content is less than 25 weight%.

52. (canceled)

53. (currently amended) A composition as defined in ~~claims~~ claim 1 ~~and~~ or 15 wherein said drug has a dose to aqueous solubility ratio greater than 100.

54. (currently amended) A composition as defined in ~~claims~~ claim 1 ~~and~~ or 15 wherein said drug is crystalline when undispersed.

55. (currently amended) A composition as defined in ~~claims~~ claim 1 ~~and~~ or 15 having a drug:polymer weight ratio between 1:0.5 and 1:20.

56. (currently amended) A composition as defined in ~~claims~~ claim 1 ~~and~~ or 15 having a drug:polymer weight ratio between 1:1 and 1:20.